ConductScience.org, home

Paper9517872

Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy.

Napoli PA and 6 others. Eur J Epidemiol, 1998. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy. Papers, record 9517872. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9517872

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy.
PubMed
Journal
Eur J Epidemiol
PubMed
Year
1998
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.23
iCite
Revised in PubMed
2026-10-16
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Napoli PAP A
2Dorrucci MM
3Serraino DD
4Pezzotti PP
5Franceschi SS
6Vella SS
7Rezza GG

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-HIV AgentsMajor topic
HIV InfectionsMajor topic
PneumocystisMajor topic
Pneumonia, PneumocystisMajor topic
Practice Patterns, Physicians'Major topic
Adolescent
Adult
CD4 Lymphocyte Count
Child
Female
Humans
Italy
Male

Source PubMed

Download CSV of topics

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18709686Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.Lancet1996https://conductscience.org/library/papers/8709686PubMed
22203263State-of-the-art conference on azidothymidine therapy for early HIV infection.Am J Med1990https://conductscience.org/library/papers/2203263PubMed
37985892Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.Ann Intern Med1995https://conductscience.org/library/papers/7985892PubMed
41970466
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Ann Intern Med1990https://conductscience.org/library/papers/1970466PubMed
58094208Expanded European AIDS case definition.Lancet1993https://conductscience.org/library/papers/8094208PubMed
68813038A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.N Engl J Med1996https://conductscience.org/library/papers/8813038PubMed
78656507Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.JAMA1996https://conductscience.org/library/papers/8656507PubMed
83299089The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.N Engl J Med1987https://conductscience.org/library/papers/3299089PubMed
97491007Impact of treatment and prophylaxis on presentation and survival of patients with AIDS in Milan.Lancet1995https://conductscience.org/library/papers/7491007PubMed
108151850Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group.JAMA1994https://conductscience.org/library/papers/8151850PubMed
117901434
Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients.
JAMA1993https://conductscience.org/library/papers/7901434PubMed
128097082Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.Ann Intern Med1993https://conductscience.org/library/papers/8097082PubMed
138806255Will we ever know when to treat HIV infection?BMJ1996https://conductscience.org/library/papers/8806255PubMed
148581117The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: projections using data to the end of 1994.Commun Dis Rep CDR Rev1996https://conductscience.org/library/papers/8581117PubMed
158096582Preliminary analysis of the Concorde trial. Concorde Coordinating Committee.Lancet1993https://conductscience.org/library/papers/8096582PubMed
168658159HIV therapeutics.Science1996https://conductscience.org/library/papers/8658159PubMed
178633824Protease inhibitors for HIV infection.Ann Intern Med1996https://conductscience.org/library/papers/8633824PubMed
188813990Antiretroviral drugs for AIDS.Lancet1996https://conductscience.org/library/papers/8813990PubMed
198172439Prophylaxis for opportunistic infections in patients with HIV infection.Ann Intern Med1994https://conductscience.org/library/papers/8172439PubMed
201969115
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
N Engl J Med1990https://conductscience.org/library/papers/1969115PubMed

See all 32 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
31999715Impact of chemorophylaxis policy for AIDS-immunocompromised patients on emergence of bacterial resistance.PLoS One2020https://conductscience.org/library/papers/31999715PubMed
11287693Sexual behaviour of heterosexual individuals with HIV infection naive for antiretroviral therapy in Italy.Sex Transm Infect2001https://conductscience.org/library/papers/11287693PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9517872

GET https://conductscience.org/api/papers/v1/9517872/references?page=2